7900 ICP-MS Increases Efficiency - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

7900 ICP-MS Increases Efficiency


Pharmaceutical Technology
Volume 38, Issue 3, pp. 14

The 7900 ICP-MS from Agilent Technolgies is a redesign of the 7700 Series. The instruments high-matrix technology allows laboratories to measure samples containing up to 25% total dissolved solids. This is 10 times higher than the current benchmark held by the 7700 ICP-MS, according to the company. The 7900’s new interface design, expansion-stage vacuum system, and orthogonal detector system (ODS) reduce background and improve sensitivity, improving signal to noise for 10-fold lower detection limits, according to the company. The patented ODS technology delivers up to 11 orders of magnitude dynamic range, from sub-ppt to percent-level concentrations, which enables users to measure trace elements and majors in the same run. In addition, the redesigned MassHunter software features a simpler user interface along with increased method automation capabilities.

Agilent Technologies

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here